Why research in medicine needs a step back? by Fais, Stefano
E
d
it
o
r
ia
l
3
Ann Ist Super Sanità 2020 | Vol. 56, No. 1: 3-5
DOI: 10.4415/ANN_20_01_02
Editorial
Why research in medicine needs  
a step back?
Stefano Fais 
Dipartimento di Oncologia e Medicina Molecolare, Istituto Superiore di Sanità, Rome, Italy
Discovery needs luck, invention, intellect - 
none can do without the other 
Johann Wolfgang Goethe, a discoverer himself
Financial Times in 2008 published an apparently pro-
vocative article with the title “Drug research needs ser-
endipity” [1]. In this visionary article the authors state 
that in the last two decades the Pharma industry did not 
introduce in the market new drugs that showed some 
effectiveness against major diseases, despite the huge 
investment; and they tried to propose some explanation 
for this. In their own words “What went wrong? The 
answer, we suggest, is the mis-measure of uncertainty, 
as academic researchers underestimated the fragility 
of their scientific knowledge, while pharmaceuticals 
executives overestimated their ability to domesticate 
scientific research”; and again “Medical research is par-
ticularly hampered by the scarcity of good animal mod-
els for most human disease, as well as by the tendency 
of academic science to focus on the ‘bits and pieces’ 
of life – DNA, proteins, cultured cells – rather than on 
the integrative analysis of entire organisms, which can 
be more difficult to study”. I guess all the readers of 
these few sentences should realize that pharmaceuti-
cal industries have failed in their investment and the 
authors of the article provide an explanation: the aca-
demic researchers have overestimated their findings 
and the headquarters of the Pharmas were wrongly 
pretty sure to manage for a perfect control of what 
came from the scientific research. One paradox of this 
low effectiveness of the new drugs is that a new field 
in pharmacology is to discover the off targetting of the 
known drugs through their side effects [2] and this is 
leading to think about the use of drugs designed to be 
specific for a disease for the treatment of other diseases. 
But this is not surprising being the vast majority of the 
drugs that pioneered the pharmacology of neurologic 
diseases thought for other uses [3]. From the whole of 
this dreadful awareness some doubts may originate on 
the future of the current research, that is going without 
breaks in the same direction. However, the authors pro-
vide a possible attempt to adjust the sight, to course cor-
rect the way, all in all to change the strategy of research 
in medicine in order to get to results that really may 
change the health and therefore the fate of the whole 
humanity. They wrote that in the past the majority of 
the discoveries were done mostly through serendipity. 
In fact, serendipity was a fairly common occurrence in 
science. However, some information is needed on the 
origin of the word “serendipity”. The term was coined 
by Horace Walpole on January 28th of 1754 in one of 
the letters written to his friend Horace Mann. Walpole 
coined the term influenced by the reading of The three 
princes of serendip by the Persian poet Kushrau. In the 
story three princes are expelled from Serendip (then 
Ceylon and in modern day Sri Lanka), and along their 
travels they make discoveries due to sheer luck. The 
story of how Walpole had access to this literary piece is 
in itself full of serendipitous anecdotes and difficulties, 
however what is important to know for our purposes is 
that “serendipity” originally referred to discoveries by 
good luck or happy accidents [3].
We had clear examples in the past of discoveries that 
really changed the natural history of devastating dis-
eases, such as infectious diseases, through incidental 
findings, that we can well re-call amazing moments of 
serendipity. The most known example of this is the dis-
covery of penicillin. Fleming was studying Staphylococ-
cus when one of his culture plates had become contami-
nated and developed a mold that created a bacteria-free 
circle. Then he found within the mold a substance very 
active against the vast majority of the bacteria infecting 
the human beings [4]. However, the Fleming’s example 
is the most known but for sure not the only one we can 
provide. One other example, while much less known, is 
that of the 1931 Nobel Prize Otto H. Warburg. He left 
overnight some plates containing tumor cells seeded 
in culture medium in the laboratory’s incubator with 
the usual 37 °C and O2/CO2 atmosphere. The morn-
ing after he realized that the O2 dropped down within 
the incubator, expecting to find all the cells dead due 
to the hypoxic conditions; while the cells were pretty 
well and after an initial astonishment he thought that 
probably cancer cells did not need oxygen to live. After 
a series of experiments his conclusion was that differ-
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ently to normal cells cancer cells do not need oxygen 
for their metabolism, while they fermentate sugar pro-
ducing lactate, thus contributing to extracellular acidi-
fication. Warburg has become a mentor for scientists 
thinking that tumor acidity is a common phenotype of 
cancers, and that an antiacidic therapy is at list to be 
implemented with the current anti-cancer approach. 
The Warburg’s discovery on tumor metabolism con-
vinced me that it is crucial in science to have a look 
to what is occurring with an open mind; not thinking 
that what apparently looks a failure of your experiment 
is actually a failure, but hopefully something that may 
represent a discovery [5, 6]. Therefore, we should iden-
tify serendipity as part of the scientific process. With 
this approach my group of research got to nonmain-
stream discoveries, including the evidence that proton 
pump inhibitors (PPI) have a clear anti-tumor effect 
and improve the effectiveness of other drugs as well, 
in turn leading to clinical studies supporting the use 
of PPI in treatment of patients with different cancers 
[7-19]; that tumor cells face off the low nutrient sup-
ply of tumors by feeding on other cells, thus becoming 
cannibal [20-24], and sharing this activity with unicel-
lular microorganisms [23], together with sharing spe-
cific cannibalism-related genes [24]; that cancer cells 
under the pressure of a very hostile microenvironment 
release a huge amount of nanovesicles that are spilled 
over the body, representing the major determinants of 
tumor metastasis [25-38].
Max Planck said “Science progresses not because sci-
entists change their minds, but rather because scientists 
attached to erroneous views die, and are replaced” and 
Otto Warburg used the same words when he realized 
the lack of acceptance of his ideas. Probably, we should 
re-think to research in medicine with a mind sufficient-
ly unbiased from mainstream infrastructures, probably 
paying more attention to potential “unexpected discov-
eries”. Probably, serendipity should be considered an 
essential part of the scientific method and, particularly, 
a tool for progress, and it should be taken as a rational 
approach to scientific practice, an attitude, and a happy 
accident. We should not think to serendipity as merely 
a luck, or chance, or happenstance; rather to a process 
in which a fortunate event leads to a discovery of a new 
solution for a problem unexpectedly.
It is hard to talk about a nonmainstream approach 
in Research in medicine [39], but this article was written 
with the hope to give only a contribute aimed at trigger-
ing a new deal in science in which to think and watch 
will represent a successful strategy.
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